Survodutide vs Tesofensine
A side-by-side research comparison of Survodutide and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Survodutide | Tesofensine |
|---|---|---|
| Full name | Survodutide (Dual GLP-1/Glucagon Agonist) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Phase 3 Clinical Trial |
| Mechanism | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 4,500 Da (approximate) | 329.4 Da |
| Half-life | 5-7 days | 8-10 days |
| Bioavailability | High (SubQ) | High (oral ~93%) |
| Typical dose | 0.6-6.0 mg | 0.25-0.5 mg |
| Frequency | Once weekly | Once daily |
| Route | Subcutaneous | Oral |
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.